Vaccination with the Leishmania major ribosomal proteins plus CpG oligodeoxynucleotides induces protection against experimental cutaneous leishmaniasis in mice

被引:53
|
作者
Iborra, Salvador [3 ]
Parody, Nuria [1 ]
Abanades, Daniel R. [1 ]
Bonay, Pedro [1 ]
Prates, Deboraci [2 ]
Novais, Fernanda O. [2 ]
Barral-Netto, Manoel [2 ]
Alonso, Carlos [1 ]
Soto, Manuel [1 ]
机构
[1] Univ Autonoma Madrid, Fac Ciencias, Dept Biol Mol, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain
[2] Fundacao Oswaldo Cruz FIOCRUZ, Ctr Pesquisas Goncalo Moniz, BR-296710 Salvador, BA, Brazil
[3] Inst Salud Carlos III, Ctr Nacl Microbiol, Unidad Inmunol Viral, Madrid 28220, Spain
关键词
Leishmania; BALB/C mice; C57BL/6; mice; Th1/Th2 immune responses; Ribosomal proteins; Vaccines;
D O I
10.1016/j.micinf.2008.06.002
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In the present work we analyze the antigenicity of Leishmania major ribosomal proteins (LRP) in infected BALB/c mice. We show that BALB/c mice vaccinated with LRP in the presence of CpG oligodeoxynucleotides (CpG-ODN) were protected against the development of dermal pathology and showed a reduction in the parasite load after challenge with L. major. This protection was associated with the induction of an IL-12 dependent specific-IFN-gamma response mediated mainly by CD4(+) T cell, albeit a minor contribution of CD8(+) T cells cannot be ruled out. Induction of Th1 responses against LRP also resulted in a reversion of the Th2 responses associated with susceptibility. A marked reduction of IgG1 antibody titer against parasite antigens besides an impaired IL-4 and IL-10 cytokine production by parasite specific T cells was observed. In addition, we show that the administration of the LRP plus CpG-ODN preparation also conferred protection in the naturally resistant C57BL/6 mice. In this strain protection was associated with a LRP specific IFN-gamma production in lymph nodes draining the challenge site. We believe that these evolutionary conserved proteins, combined with adjuvants that favor Th1 responses, may be relevant components of a pan-Leishmania vaccine. (c) 2008 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:1133 / 1141
页数:9
相关论文
共 50 条
  • [31] Vaccination with a novel recombinant Leishmania antigen plus MPL provides partial protection against L. donovani challenge in experimental model of visceral leishmaniasis
    Bhardwaj, Suvercha
    Vasishita, R. K.
    Arora, Sunil K.
    EXPERIMENTAL PARASITOLOGY, 2009, 121 (01) : 29 - 37
  • [32] DNA vaccination with linear minimalistic (MIDGE) vectors confers protection against Leishmania major infection in mice
    López-Fuertes, L
    Pérez-Jiménez, E
    Vila-Coro, AJ
    Sack, F
    Moreno, S
    Konig, SA
    Junghans, C
    Wittig, B
    Timón, M
    Esteban, M
    VACCINE, 2002, 21 (3-4) : 247 - 257
  • [33] BCG-INDUCED PROTECTION AGAINST CUTANEOUS LEISHMANIA-MAJOR INFECTIONS IN P/J MICE
    FORTIER, AH
    MOCK, BA
    MELTZER, MS
    NACY, CA
    FEDERATION PROCEEDINGS, 1985, 44 (04) : 983 - 983
  • [34] Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge
    Dumais, N
    Patrick, A
    Moss, RB
    Davis, HL
    Rosenthal, KL
    JOURNAL OF INFECTIOUS DISEASES, 2002, 186 (08): : 1098 - 1105
  • [35] VACCINATION AGAINST MURINE CUTANEOUS LEISHMANIASIS BY USING LEISHMANIA-MAJOR ANTIGEN LIPOSOMES - OPTIMIZATION AND ASSESSMENT OF THE REQUIREMENT FOR INTRAVENOUS IMMUNIZATION
    KAHL, LP
    SCOTT, CA
    LELCHUK, R
    GREGORIADIS, G
    LIEW, FY
    JOURNAL OF IMMUNOLOGY, 1989, 142 (12): : 4441 - 4449
  • [36] VACCINATION OF VERVET MONKEYS AGAINST CUTANEOUS LEISHMANIASIS USING RECOMBINANT LEISHMANIA-MAJOR SURFACE GLYCOPROTEIN (GP63)
    OLOBO, JO
    ANJILI, CO
    GICHERU, MM
    MBATI, PA
    KARIUKI, TM
    GITHURE, JI
    KOECH, DK
    MCMASTER, WR
    VETERINARY PARASITOLOGY, 1995, 60 (3-4) : 199 - 212
  • [37] Vaccination with TAT-LACK fusion proteins protects mice against progressive infection with Leishmania major
    Moelle, K
    Butsch, F
    Tada, Y
    Lopez, S
    Shibagaki, N
    Knop, J
    Udey, MC
    Von Stebut, E
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2005, 125 (03) : A81 - A81
  • [38] Therapeutic Effect of Hedera helix Alcoholic Extract Against Cutaneous Leishmaniasis Caused by Leishmania major in Balb/c Mice
    Hooshyar, Hossein
    Talari, Safarali
    Feyzi, Fatemeh
    JUNDISHAPUR JOURNAL OF MICROBIOLOGY, 2014, 7 (04)
  • [39] Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran
    Sharifi, I
    FeKri, AR
    Aflatonian, MR
    Khamesipour, A
    Nadim, A
    Mousavi, MRA
    Momeni, AZ
    Dowlati, Y
    Godal, T
    Zicker, F
    Smith, PG
    Modabber, F
    LANCET, 1998, 351 (9115): : 1540 - 1543
  • [40] Evaluation of immune responses and analysis of the effect of vaccination of the Leishmania major recombinant ribosomal proteins L3 or L5 in two different murine models of cutaneous leishmaniasis
    Ramirez, Laura
    Santos, Diego M.
    Souza, Ana P.
    Coelho, Eduardo A. F.
    Barral, Aldina
    Alonso, Carlos
    Escutia, Marta R.
    Bonay, Pedro
    de Oliveira, Camila I.
    Soto, Manuel
    VACCINE, 2013, 31 (09) : 1312 - 1319